BUSINESS - CERVICAL CANCER
Cervical Cancer detector may improve on Pap Smears
BY OUR PHARMA CORRESPONDENT
CHERRY HILL, N.J., June 28 /PRNewswire/ -- Physicians may soon give their patients immediate
and accurate results during a routine pap smear exam designed to screen for any abnormalities in
A medical device in development may be able to identify molecular change in the cervix and
optically assess if the cervix is normal, malignant, dysplastic (pre-cancer) or benign.
Mediscience Technology Corp. in collaboration with Dr. Robert Alfano and his team at the City
College of New York (CUNY) have developed the Cancer Detection Ratiometer (CD-R), which is
expected to enter clinical trials (http://www.medisciencetech.com/).
"Rapid results are important because, although cervical cancer develops slowly, the earlier
cancerous or pre-cancerous cervical conditions are detected, the greater the likelihood for a cure, "
says Dr. Stephane Lubicz, a gynecological oncologist based in New York. "Many things can interfere
with accurate pap test results; among them not enough cells on the slide or improperly preparing
The CD-R can optically assess cervical tissue using auto-florescent lighting at pre-established
wavelengths to diagnose the state of the cervix without removing it from the body. The technology
immediately reports to the physician any abnormal cell activity on the CRT screen. This process may
eventually eliminate the long waiting for pap smear results.
"The CD-Ratiometer has shown sensitivity and specificity equal or greater than ninety percent in
vitro studies. The technology will not give false results, and so far has no-known serious side
effects," says Dr. Lubicz.
The American Cancer Society (ACS) estimates that 10,500 cases of invasive cervical cancer will be
diagnosed in the United States in 2005, and 3,900 women will die from the disease. The five-year
survival rate for invasive cervical cancer that is caught at its earliest stage is nearly 100 percent.
Cervical cancer rates are higher among older women. Half of women diagnosed with cervical
cancer are between the ages of 35 and 55.
RELATED CANCER STORIES
Drug for advanced colorectal cancer gets marketing nod in Canada
Advanced prostate cancer therapy Provenge seeks marketing nod in US
New kidney cancer drug seeks EU nod
Breast cancer drug Aromasin approved in Europe: Pfizer
15 Sep, 2005
Lung cancer vaccine trials promising: Introgen
Rituxan, cancer drug can treat rheumatoid arthritis
2 September, 2005
Novartisí drug for breast cancer recurrence to be given priority review in US
31 August, 2005
New cancer combo therapy results
25 August, 2005
Cell Therapeutics to seek approval for lung cancer therapy in US and Europe
25 August, 2005
Aspirin stops colon cancer, but may trigger bleeding
24 August, 2005
Skin disease drug turns into anti-tumor therapy for cancer
22 August, 2005
"Breast cancer chances higher due to fried chips"
22 August, 2005
Pfizer files NDA for Sutent in US
Alcohol linked cancers: Acetaldehyde in spot light
10 August, 2005
Chemokine gets US patent for novel cancer drug
20 June, 2005
Prohibitive costs mar cancer therapy
15 July, 2005
may help cure cancer by killing cancer cells
CALGARY, Alberta, June 28
Cancer detector may improve on Pap Smears
CHERRY HILL, N.J., June 28
Novartis has better breast cancer treatment
Toronto, Ontario, April 11, 2005
Roche, Novartis lead on novel cancer therapies
23 July, 2005
investigational drug reduces tumor
14 May, 2005